Creatine kinase U-type, mitochondrial, also called ubiquitous mitochondrial creatine kinase (uMtCK), is in humans encoded by CKMT1A gene. CKMT1A catalyzes the reversible transfer of the γ-phosphate group of ATP to the guanidino group of Cr to yield ADP and PCr. The impairment of CKMT1A has been reported in ischaemia, cardiomyopathy, and neurodegenerative disorders. Overexpression of CKMT1A has been reported related with several tumors.[1][2][3]

creatine kinase, mitochondrial 1A
Identifiers
SymbolCKMT1A
Alt. symbolsCKMT1
NCBI gene548596
HGNC31736
RefSeqNM_001015001
UniProtP12532
Other data
EC number2.7.3.2
LocusChr. 15 q15
Search for
StructuresSwiss-model
DomainsInterPro

Structure edit

Gene edit

The CKMT1A gene lies on the chromosome location of 15q15.3 and consists of 11 exons.

Protein edit

CKMT1A consists of 417 amino acids and weighs 47037Da. CKMT1A is rich in amino acids with hydroxyl-containing and basic side chains.[4]

Function edit

There are four distinct types of CK subunits in the tissue of mammals, which are expressed species specifically, developmental stage specifically, and tissue specifically. Ubiquitously expressed, CKMT1A is located in the mitochondrial intermembrane space and form both homodimeric and homooctameric molecules that are readily interconvertible.[5] Like all the other CK isoenzymes, CKMT1A catalyzes the reversible transfer of the γ-phosphate group of ATP to the guanidino group of Cr to yield ADP and PCr.[6] According to the “transport” (“shuttle”) hypothesis for the CK system, after synthesis within the mitochondrial matrix, the γ-phosphate group of ATP is transferred by CKMT1A in the mitochondrial intermembrane space to Cr to yield ADP plus PCr.

Clinical significance edit

As an enzyme central to cell energetics, CKMT1A is often impaired in pathological situations. CKMT1A is known as a primary target of oxidative and radical-induced molecular damage; and the impairment of CKMT1A has been reported in ischaemia, cardiomyopathy, and neurodegenerative disorders due to the failure in maintaining metabolic homeostasis.[7][8] Overexpression of uMtCK has been reported for several tumors with poor prognosis and this may be the adaption of cancer cells to maintain the high growth rate.[9][10][11][12]

Interactions edit

References edit

  1. ^ Haas RC, Korenfeld C, Zhang ZF, Perryman B, Roman D, Strauss AW (February 1989). "Isolation and characterization of the gene and cDNA encoding human mitochondrial creatine kinase". The Journal of Biological Chemistry. 264 (5): 2890–7. doi:10.1016/S0021-9258(19)81696-4. PMID 2914937.
  2. ^ Stachowiak O, Schlattner U, Dolder M, Wallimann T (July 1998). "Oligomeric state and membrane binding behaviour of creatine kinase isoenzymes: implications for cellular function and mitochondrial structure". Molecular and Cellular Biochemistry. 184 (1–2): 141–51. doi:10.1023/A:1006803431821. PMID 9746318. S2CID 22668868.
  3. ^ Lipskaya TY (October 2001). "Mitochondrial creatine kinase: properties and function". Biochemistry. Biokhimiia. 66 (10): 1098–111. doi:10.1023/A:1012428812780. PMID 11736631. S2CID 32593074.
  4. ^ Refrégier G, Le Gac M, Jabbour F, Widmer A, Shykoff JA, Yockteng R, Hood ME, Giraud T (March 2008). "Cophylogeny of the anther smut fungi and their caryophyllaceous hosts: prevalence of host shifts and importance of delimiting parasite species for inferring cospeciation". BMC Evolutionary Biology. 8 (1): 100. Bibcode:2008BMCEE...8..100R. doi:10.1186/1471-2148-8-100. PMC 2324105. PMID 18371215.
  5. ^ Sieroń L (December 2007). "Poly[bis-(μ(2)-formato-κO:O')(quinoxaline-κN)copper(II)]". Acta Crystallographica Section E. 64 (Pt 1): m53. doi:10.1107/S1600536807063015. PMC 2914937. PMID 21200625.
  6. ^ Wyss M, Kaddurah-Daouk R (July 2000). "Creatine and creatinine metabolism". Physiological Reviews. 80 (3): 1107–213. doi:10.1152/physrev.2000.80.3.1107. PMID 10893433.
  7. ^ Kekelidze T, Khait I, Togliatti A, Benzecry JM, Wieringa B, Holtzman D (December 2001). "Altered brain phosphocreatine and ATP regulation when mitochondrial creatine kinase is absent". Journal of Neuroscience Research. 66 (5): 866–72. doi:10.1002/jnr.10060. PMID 11746413. S2CID 20976134.
  8. ^ Schlattner U, Tokarska-Schlattner M, Wallimann T (February 2006). "Mitochondrial creatine kinase in human health and disease". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1762 (2): 164–80. doi:10.1016/j.bbadis.2005.09.004. PMID 16236486.
  9. ^ Cevenini R, Varotti C, Rumpianesi F, Donati M, Tosti A, Negosanti M (1980-01-01). "Non-gonococcal urethritis: epidemiological and etiological study in Italy". Bollettino dell'Istituto Sieroterapico Milanese. 59 (6): 599–603. PMID 7236360.
  10. ^ Enooku K, Nakagawa H, Soroida Y, Ohkawa R, Kageyama Y, Uranbileg B, Watanabe N, Tateishi R, Yoshida H, Koike K, Yatomi Y, Ikeda H (August 2014). "Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients". International Journal of Cancer. 135 (4): 871–9. doi:10.1002/ijc.28720. PMID 24420733.
  11. ^ Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, Tateishi R, Yoshida H, Shinzawa S, Moriya K, Ohtomo N, Nishikawa T, Inoue Y, Tomiya T, Kojima S, Matsuura T, Koike K, Yatomi Y, Ikeda H (May 2014). "High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential". International Journal of Cancer. 134 (9): 2189–98. doi:10.1002/ijc.28547. PMID 24174293. S2CID 24244814.
  12. ^ Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, Kornacker B, Staratschek-Jox A, Diehl V, Wolf J (November 2001). "Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis". International Journal of Cancer. 94 (4): 513–9. doi:10.1002/ijc.1502. PMID 11745437. S2CID 5612884.
  13. ^ Cui J, Yu M, Niu J, Yue Z, Xu Z (October 2011). "Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system". Bioscience Reports. 31 (5): 429–37. doi:10.1042/BSR20100127. PMC 3971885. PMID 21370995.
  14. ^ Kwon S, Kim D, Rhee JW, Park JA, Kim DW, Kim DS, Lee Y, Kwon HJ (March 2010). "ASB9 interacts with ubiquitous mitochondrial creatine kinase and inhibits mitochondrial function". BMC Biology. 8: 23. doi:10.1186/1741-7007-8-23. PMC 2852384. PMID 20302626.

External links edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.